Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,516.00+0.84%ETH$2,488.45+0.36%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
RV

NASDAQ · RVMDW

Revolution Medicines, Inc. Warrant

Healthcare · Biotechnology

$9.77

Up+$0.20 (+2.12%)

Updated Oct 11, 2026, 7:08 AM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
154.68M
P/E ratio
-15.46
Dividend yield
0.00%
52-week range
$1.53 – $13.44
Volume
4K
Avg. volume
28.36K

Price performance · RVMDW

RVMDW price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

RVMDW closed at $9.77 after 20 trading sessions, down 14.60% for the selected period.

Last close
$9.77
Period change
-14.60%
Period low
$9.44
Period high
$11.70
Daily close
View OHLC price history
RVMDW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$9.35$9.805$9.305$9.7654K
Oct 8, 2026$10.65$10.65$8.72$9.4475.64K
Oct 7, 2026$10.50$11.10$10.50$10.769.42K
Oct 6, 2026$11.30$11.30$10.30$10.7322.12K
Oct 5, 2026$11.40$11.90$10.99$11.7011.31K
Oct 2, 2026$11.20$11.72$11.15$11.4113.7K
Oct 1, 2026$11.28$11.97$11.28$11.6020.26K
Sep 30, 2026$11.375$11.80$11.375$11.4419.95K
Sep 29, 2026$11.19$11.25$10.81$11.2514.81K
Sep 28, 2026$11.23$11.34$11.00$11.226.89K
Sep 25, 2026$10.64$12.00$10.56$11.625116.31K
Sep 24, 2026$10.10$10.95$10.01$10.7671.87K
Sep 23, 2026$9.76$10.46$9.68$9.8232.24K
Sep 22, 2026$10.085$10.29$9.96$10.0333.87K
Sep 21, 2026$10.167$10.167$9.89$9.9813.34K
Sep 18, 2026$10.29$10.29$9.50$9.6463.71K
Sep 17, 2026$10.36$11.00$10.20$10.29546K
Sep 16, 2026$10.69$10.95$10.0601$10.4619.68K
Sep 15, 2026$11.45$11.45$11.10$11.306.23K
Sep 14, 2026$11.125$11.50$10.81$11.43543.95K

Latest RVMDW news

The latest Smart Investors Daily articles mentioning RVMDW.

Stock researchCompany · Overview

RVMDW research

Overview

Company profile and research snapshot.

Company profile

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 25, 2026

Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold?

Pre-commercial precision oncology firms often face steep financial trade-offs, where absent return on invested capital/ROIC and negative operating cash flows are the price of admission for long-term clinical innovation. IDEAYA Biosciences (NASDAQ:IDYA) operates from a position of relative balance sheet strength, backed by $1.24 billion in cash, cash equivalents, and marketable securities that extend its […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By